ARIAD Announces Commercial Availability of Iclusig for Patients with Refractory Philadelphia-Positive Leukemias in US
January 17, 2014 at 07:36 AM EST
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA ) today announced the commercial availability of Iclusig^® (ponatinib) for adult patients with refractory chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia in the United States. ARIAD has begun shipping Iclusig to Biologics, Inc., its exclusive specialty pharmacy, which is now filling prescriptions from physicians and distributing the
